In aggregate, we have developed a discovery platform for transcriptional changes related to polycystin function and discovered Glis2 as a potentially tractable therapeutic target for treatment of ADPKD. This evidence concerns the gene GLIS2 and autosomal dominant polycystic kidney disease.